Neoadjuvant Strategies for Triple Negative Breast Cancer: ‘State-of-the-art’ and Future Perspectives

Author(s): Luisa Carbognin, Jenny Furlanetto, Cecilia Vicentini, Rolando Nortilli, Sara Pilotto, Matteo Brunelli, Francesca Pellini, Giovanni Paolo Pollini, Emilio Bria, Giampaolo Tortora.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 15 , Issue 1 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Neoadjuvant therapy for triple negative breast cancer (TNBC) has recently generated growing interest given the more aggressive biologic characteristics of such subtype and the lack of approved targeted therapies. Systemic chemotherapy represents the mainstay of treatment for TNBC. Although neoadjuvant chemotherapy has consistently demonstrated higher response rates for TNBC compared to non-TNBC, and the pathological complete response predicts long-term outcome, most patient display residual disease with a higher risk of relapse. In order to improve the outcome of TNBC new chemotherapic combinations, including platinum agents, and different targeted agents such as antiangiogenetics, poly-ADP ribose polymerase (PARP) inhibitors and other small molecule inhibitors are being evaluated in neoadjuvant setting. Currently, the research is ongoing to further characterize TNBC from a phenotypical and molecular perspective, in order to identify potential new target agents and to individualize the treatment. In this regard, the neoadjuvant setting may represent the best potential scenario to assess the activity and the sensitivity of novel agents.

Keywords: Breast cancer, chemotherapy, neoadjuvant, targeted therapy, triple negative.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [15 - 25]
Pages: 11
DOI: 10.2174/1871520614666141019191616

Article Metrics

PDF: 69